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Abstract
Background: Steroid resistant (SR) asthma is characterized by persistent airway inflammation that fails to resolve
despite treatment with high doses of corticosteroids. Furthermore, SR patient airways show increased numbers
neutrophils, which are less responsive to glucocorticoid. The present study seeks to determine whether
dexamethasone (DEX) has different effect on neutrophils from steroid sensitive (SS) asthmatics compared
to SR asthmatics.
Methods: Adults with asthma (n = 38) were classified as SR or SS based on changes in lung FEV1% following
a one-month inhaled corticosteroid (ICS) treatment. Blood samples were collected from all patients during their
first visit of the study. Neutrophils isolated from the blood were cultured with dexamethasone and/or atopic
asthmatic serum for 18 h. The mRNA expression of mitogen-activated protein kinase phosphatase-1 (MKP-1),
a glucocorticoid transactivation target, and glucocorticoid-induced transcript 1 (GLCCI1), an early marker of
glucocorticoid-induced apoptosis whose expression was associated with the response to inhaled glucocorticoids
in asthma , was determined by real-time PCR, and ELISA was used to assess the pro-inflammatory cytokine IL-8
levels in the supernatant. Constitutive neutrophil apoptosis was detected by flow cytometry.
Results: DEX significantly induced MKP-1 expression in both patients with SS and SR patients in a concentration-
dependent manner, but greater induction was observed for SS patients at a low concentration (10−6 M).
Asthmatic serum alone showed no MKP-1expression, and there was impaired induction of MKP-1 by DEX in SR
asthma patients. The expression of GLCCI1 was not induced in neutrophils with DEX or DEX/atopic asthmatic
serum combination. Greater inhibition of IL-8 production was observed in neutrophils from patients with SS
asthma treated with DEX/atopic asthmatic serum combination compared with SR asthma patients, though DEX
alone showed the same effect on neutrophils from SS and SR asthma patients. Meanwhile, DEX dependent
inhibition of constitutive neutrophil apoptosis was similar between SS asthma and SR asthma patients.
Conclusions: DEX exerted different effects on neutrophils from patients with SS asthma and SR asthma, which
may contribute to glucocorticoid insensitivity.
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Background
Bronchial asthma is a chronic airway inflammatory
disease that affects more than 300 million people world-
wide, and this number is predicted to rise to 400 million
by 2020 [1, 2]. The defining features of asthma are
inflammation, airway hyperresponsiveness, reversible
airway obstruction, and airway structural remodeling
[3, 4]. A large array of cytokines, chemokines, and
other pro-inflammatory mediators released by both
immune-inflammatory and airway structural cells con-
tribute to the pathophysiology asthma [5–7]. Consider-
able evidence shows that airway inflammation is a
major factor in asthma pathogenesis, and that bron-
chial hyperresponsiveness in asthma often correlates
with disease severity [8].
Glucocorticoids are potent anti-inflammatory drugs
used as a mainstay treatment for asthma [9]. The anti-
inflammatory effects of corticosteroids are mediated
through the glucocorticoid receptor (GR), which binds
to glucocorticoid response elements (GREs) to regu-
late the transcription of specific genes [10]. In most
patients, asthma symptoms can be well controlled
with low doses of inhaled corticosteroids (ICSs). How-
ever, some patients require higher doses of ICSs or
even oral corticosteroids to achieve optimal control,
indicating that these asthma patients might be rela-
tively resistant to the anti-inflammatory actions of
corticosteroids (steroid resistant asthma). Between 10
and 25% of asthmatics are steroid resistant (SR), and
do not respond to glucocorticoids (GCs) therapy [11–13].
Several studies found that steroid resistant (SR) asthmatics
do not have eosinophils in their airways, but instead have
neutrophils [14].
The role of neutrophils in bronchial asthma patho-
genesis is controversial [15]. Previous studies demon-
strated that neutrophils play a regulatory role in
asthma, since they synthesize and release an array of in-
flammatory mediators that trigger the development of
asthma [16]. Severe asthma, persistent asthmatic status,
acute asthma exacerbation, and corticosteroid-resistant
asthma are associated with increased numbers of neu-
trophils in peripheral blood and bronchoalveolar lavage
fluid (BALF), sputum or bronchial biopsy samples from
asthma patients [17, 18]. Neutrophils are generally con-
sidered to be less responsive to GCs, since events in-
volved in neutrophil activation, including adherence,
chemotaxis, degranulation, and arachidonic acid metab-
olite release are not effectively inhibited by glucocorti-
coids [19]. Many studies showed that SR asthma was
associated with impaired in vitro and in vivo respon-
siveness of monocytes and T lymphocytes to the sup-
pressive effects of GCs [20–22], but little is known
about the responsiveness of neutrophils. In this study,
we examined whether neutrophils from SS asthmatics




Thirty-eight adult asthmatic patients between the ages
of 18 and 65 years were recruited from Tongji Hospital.
The diagnosis of asthma was based on the Global
Initiative for Asthma (GINA) guidelines. All subjects
had a doctor’s diagnosis of symptomatic asthma and
demonstrated evidence of airways hyperresponsiveness
(PD20 methacholine < 2.5 mg) and/or bronchodilator
responsiveness (>12% improvement in FEV1% predicted
following inhalation of 200 μg salbutamol). Participants
were excluded if they were current smokers or ex-
smokers with a history more than 10 pack-years, had a
course of oral corticosteroids, or a respiratory tract infec-
tion in the previous 4 weeks. The clinical characteristics of
these participants are described in detail in Table 1.
Patients’ clinical responses to corticosteroids were de-
termined based on change in prebronchodilator FEV1
percent predicted after a one-month ICS treatment.
Asthmatics were defined as SR if they had less than
15% improvement in baseline prebronchodilator FEV1.
Among the 38 patients, 26 and 12 were classified as
having SS and SR asthma, respectively. Blood samples
were collected from all patients at their first visit of the
study. Written informed consent was obtained from all
subjects and the study was approved by the ethics com-
mittee of Tongji Hospital, Tongji Medical College,
Huazhong University of Science and Technology.
Neutrophil isolation and cell culture
Neutrophils were separated from the heparinized periph-
eral blood of asthmatics using Ficoll-Hypaque gradient
centrifugation. Briefly, peripheral blood was mixed with
hydroxyethyl starch 550 (HES-TBD 550, TBDscience,
Tianjin, China) and PBS, and allowed to sediment for
Table 1 Patient characteristics
Patients with SS
asthmatic (n = 26)
Patients with SR
asthmatic (n = 12)
Age(y), mean ± SD 43.81 ± 2.54 40.25 ± 2.9
Sex (male/female) 12/14 7/5
Duration of asthma (y),
mean ± SD
4.92 ± 1.51 4.0 ± 1.83
Baseline FEV1 (% predicted),
mean ± SD
70.77 ± 3.71 75.43 ± 4.18
FEV1/FVC (%), mean ± SD 61.62 ± 1.53 67.6 ± 3.97
FEV1 (% change after one
month treatment), mean ± SD
35.65 ± 3.70 9.23 ± 1.15***
FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, ICS inhaled
corticosteroid, LABA long-acting b-agonist
***P < 0.001 compared with patients with SS asthma
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30 min. The leukocyte containing supernatant was then
carefully layered onto Ficoll-Hypaque gradient. After
centrifugation at 800 g for 25 min, all the layers above
the red cells were removed. The cells were washed after
hypotonic lysis to remove erythrocytes and then resus-
pended at 5 × 105/ml in RPMI 1640 medium (GIBCO
Laboratories, Grand Island, NY) with 1% penicillin-
streptomycin (KeyGEN, Nanjing, China) and 10% FBS
(GIBCO Laboratories, Grand Island, NY) or 10% atopic
asthmatic serum. This method routinely yielded a purity
>98% as determined by Wright-Giemsa staining. The
atopic asthmatic serum was obtained from allergic
asthmatic patients with serum IgE levels >1000 IU/ml.
Isolated neutrophils were treated with dexamethasone
(Sigma–Aldrich, St. Louis, MO USA) at a concentration of
10−6 M or 10−4 M or left unstimulated for 18 h.
Assessment of apoptosis
To detect neutrophil apoptosis, an annexinV–fluorescein
isothiocyanate (FITC) apoptosis detection kit (KGA108,
KeyGEN, Nanjing, China) was used according to the man-
ufacturer’s protocol. Briefly, neutrophils were washed
twice in ice-cold PBS and resuspended in 500 μl binding
buffer containing 5 μl FITC-labeled annexin V and 5 μl
propidium iodide (PI) for 15 min at room temperature in
the dark. Apoptotic neutrophils were analyzed using a
FACSCalibur with CellQuest software (BD Biosciences),
and were determined as the percentage of cells showing
annexin V+/PI- and annexin V+/PI+ staining.
Enzyme-linked immunosorbent assay (ELISA)
The concentrations of IL-8 in cell culture supernatants
were measured with a sandwich enzyme-linked immuno-
sorbent assay (ELISA) using a Human IL-8 DuoSet ELISA
kit (R&D Systems, Minneapolis, MN, USA) according to
the manufacturer’s instructions. Briefly, a 96-well micro-
plate was coated with capture antibody and incubated
overnight at room temperature. Then, block plates by
incubating with Block Buffer at room temperature for
1 h. The standards or cell supernatants were added to
the plate; Detection Antibody, and streptavidin-HRP
was added. After removal the unbound material by a
washing procedure, substrate solution [1:1 mixture of
color reagent A (H2O2) and color reagent B (tetra-
methylbenzidine)] was added in the dark. To stop the
reaction, 2 N H2SO4 was added to each well. The optical
density was determined at 450 nm and a reference wave-
length of 570 nm using a spectrophotometer. Standard
curve was constructed by plotting absorbance values ver-
sus the corresponding concentration of standard. Concen-
trations were calculated based on the standard curve. The
limit of detection was 31.3 pg/mL.
RNA isolation, reverse transcription and quantitative real-
time PCR
Total RNA from cells was extracted using TRIzol re-
agent (Takara, Dalian, China) according to the manufac-
turer’s instructions using three-step nucleic acid
precipitation with 0.2 volume of chloroform, 1 volume
of isopropanol and 75% ethano. Extracted RNA was dis-
solved in 20 μL diethylpyrocarbonate-treated water.
Total RNA concentration and purity were evaluated by
spectrophotometry (NanoDrop 2000, Thermo scientific
Fisher, Waltham, MA, USA). The cDNA was prepared
from 500 ng total RNA using Prime Script RT Master
Mix (Takara, Dalian, China) following the manufacturer’s
instructions. Briefly, the reaction mixture (10 μL) con-
taining 2 μL 5 × Prime Script RT Master Mix was cycled
at 37 °C for 15 min, 85 °C for 5 s, and 4 °C for 1 min.
Real-time PCR was performed to quantify mRNA levels
using an ABI Prism 7500 Real-Time System (Applied
Biosystems, Foster City, California, USA) with SYBR
Premix Ex Taq (Takara, Dalian, China). 1 μL of cDNA
was used in 20-μL final PCR volume containing 10 μL of
SYBR Premix Ex Taq, 0.4 μL of ROX Reference Dye II,
and 0.2 μM each sense and antisense primers. The PCR
parameters were 95 °C for 30 s, followed by 40 cycles of
95 °C for 5 s and 60 °C for 34 s. Results were expressed
as 2–ΔΔCT, normalized to levels of β-actin in untreated
cells. Gene expression was reported as the relative vari-
ation (fold change) to unstimulated cell mRNA levels.
The primers used in this study were synthesized by
Sangon Biotech (Shanghai, China) and had the following
sequences: β-actin (forward, GCAAGCAGGACTATGA
CGAG and reverse, CAAATAAAGCCATGCCAATC);
GLCCI1 (forward, GGGAAGGAAGAAGTATCCAAGC
and reverse, GCGAGTACTACTGCTCCGGTA); MKP1
(forward, GCTGTGCAGCAAACAGTCGA and reverse,
CGATTAGTCCTCATAAGGTA).
Statistical analysis
Data were expressed as means ± SD. All statistical ana-
lyses were conducted using GraphPad Prism 5 software
(GraphPad, San Diego, CA, USA). Data were analyzed
by t test if the data followed a normal distribution; non-
parametric tests were applied for the data that were not
normally distributed. All statistical tests were two-tailed
and differences were considered significant at a P value
of less than 0.05.
Results
Study subjects
Clinical characteristics of the study participants are sum-
marized in Table 1. In this study patients were defined as
having SR or SS asthma based on changes in lung function
after 1 month of ICS treatment. Asthmatics were defined
as SR if they had less than 15% improvement in baseline
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prebronchodilator FEV1. The patients with SS and SR
asthma were similar in terms of demographics, duration
of asthma, and mean FEV1 at baseline. The only clinical
difference between the two patient group was changes in
lung function after ICS (mean △FEV1 percent predicted);
the patients with SS asthma showed significant improve-
ment in △FEV1 (Mean ± SD) of 35.65 ± 3.70%, whereas no
significant change in FEV1% predicted was noted in the
patients with SR asthma with a △FEV1 (Mean ± SD) of
9.23 ± 1.15%.
In vitro markers of corticosteroid responsiveness
Neutrophils were isolated from patients’ blood at their
first visit. The expression of selected gene targets was
analyzed by real time PCR after treating cells with 10−6
M or 10−4 M DEX, or DEX/asthmatic serum for 18 h.
MKP-1 was selected as a well-known glucocorticoid
transactivation target [23]. DEX significantly induced
MKP-1 expression in neutrophils from SS asthma patients
in a concentration-dependent manner to produce a 6.18 ±
1.46 (P < 0.0001) and 21.38 ± 4.96-fold (P < 0.0001) at 10−6
M and at 10−4 M DEX, respectively,relative to control cells
(Fig. 1a). Similarly, DEX significantly increased MKP-1
levels in neutrophils from patients with SR asthma by
3.61 ± 0.94-fold (P < 0.05) at 10−6 M and 18.88 ± 7.62-fold
(P < 0.01) at 10−4 M relative to control cells (Fig. 1b).
Notably, the level of MKP-1 induced by 10−6 M DEX
was significantly greater in neutrophils from patients
with SS asthma relative to patients with SR asthma (P <
0.05) (Fig. 1c). Asthmatic serum alone showed no MKP-1
expression, but when combined with DEX, asthmatic
serum impaired the induction of MKP-1 by DEX in
neutrophils from SR asthma patients (P < 0.05). (Fig. 1d).
The effects of DEX on GLCCI 1 gene expression in SS and
SR asthmatic patients
Glucocorticoid-induced transcript 1 (GLCCI1) is expressed
in both lung cells and immune cells, and its expression is
significantly enhanced by the presence of glucocorticoids
in asthma-like conditions [24]. Here we examined the ex-
pression of GLCCI1 mRNA in response to DEX with or
without asthmatic serum in neutrophils isolated from SS
and SR asthma patients. Neutrophils from participants
treated with 10−6 M or 10−4 M DEX without asthmatic
serum or DEX/asthmatic serum for 18 h. There was no
significant change in the level of GLCCI1 in neutrophils
treated with DEX from SS asthma and SR asthma patients
(Fig. 2a and b). Similarly, the levels of GLCCI1 were not af-
fected by DEX/asthmatic serum combination in SS asthma
and SR asthma patients (Fig. 2c).
DEX inhibited IL-8 production by neutrophils from SS
asthmatics and SR asthmatics
The capacity of neutrophils to produce IL-8 has been
documented both in vitro and in vivo and is a useful in-
dicator of protein synthesis by activated cells [25]. We
Fig. 1 MKP1 gene expression induced by dexamethasone (DEX) in asthmatic patients. Neutrophils were isolated from peripheral blood of
asthmatic patients and then incubated for 18 h in the absence (Con) or presence of dexamethasone (DEX) at 10−6 M or 10−4 M, with/without
atopic asthma serum (SE). Following culture, mRNA expression of MKP1 was quantified by realtime-PCR. a and b, Neutrophils respectively from SS
asthmatics (a) and SR asthmatics (b) were incubated with dexamethasone (DEX) at 10−6 M or 10−4 M. c, MKP-1 induction by DEX at 10−6 M was
significantly greater from SS asthmatics. d, Neutrophils were isolated from asthmatic patients and incubated with DEX 10−4 M, and/or asthmatic
serum (SE). * P < 0.05, ** P < 0.01, and *** P < 0.001 compared with the control groups
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measured IL-8 production in culture to examine if DEX
had different effects on activation of neutrophils isolated
from SS and SR asthma patients. Neutrophils from SS
asthmatics and SR asthmatics were incubated with 10−6 M
or 10−4 M DEX either with or without asthmatic serum for
18 h. IL-8 levels in cell culture supernatants were then
assessed by ELISA. Untreated cells produced detectable
IL-8 levels, and this level increased in the presence of asth-
matics serum from a basal level of 1183 ± 171.5 pg/mL to
1640 ± 156.3 pg/mL for SR asthma patients (Fig. 3). How-
ever, there was no significant change in SS asthma patients.
Meanwhile, DEX significantly and dose-dependently re-
duced IL-8 production in neutrophils from patients with
SS asthma and SR asthma. The inhibition was similar be-
tween SS asthma and SR asthma with either DEX at 10−6
M or 10−4 M (Fig. 3c). However, the asthmatics serum im-
paired the inhibitory activity of DEX towards neutrophils
from SR asthma (Fig. 3c). Significantly greater inhibition of
IL-8 production was observed with neutrophils from pa-
tients with SS asthma in the presence of DEX/asthmatic
serum combination when compared with neutrophils of
patients with SR asthma (P < 0 .05).
DEX inhibited constitutive apoptosis of neutrophils from
SS and SR asthma patients despite the presence of
asthmatic serum
We next evaluated whether the effect of DEX on constitu-
tive apoptosis of neutrophils in the presence or absence of
asthmatic serum differs between SS and SR asthma
patients. Constitutive apoptosis of neutrophils from SS
asthma patients was inhibited by both 10−6 M and 10−4 M
DEX, as was apoptosis of neutrophils from SR asthma pa-
tients (Fig. 4). Meanwhile, the addition of asthmatic serum
had no effect on DEX inhibition of apoptosis of neutro-
phils from SS and SR asthma patients (Fig. 4).
Discussion
Here we examined the effect of DEX on neutrophils
from SS asthmatics and SR asthmatics. The expression
of selected markers in neutrophils that reflect the re-
sponse to DEX significantly differed between SR and SS
asthmatics. The ability of DEX to induce MKP-1 expres-
sion was significantly reduced in neutrophils from SR
asthmatics compared to those from SS asthmatics. Add-
itionally, the level of GLCCI1, which is significantly asso-
ciated with the response of asthma patients to inhaled
glucocorticoids [24], was not affected by DEX in neutro-
phils from asthmatics. We also assessed IL-8 production
of neutrophil, an indicator of neutrophil activation [25].
The data demonstrated that more DEX was required to
suppress IL-8 production by SR asthmatic neutrophils
relative to SS asthmatics when asthmatic serum was
added. We next demonstrated that DEX exerted a simi-
lar effect on constitutive apoptosis of neutrophils from
SR and SS asthmatics. Thus, we concluded that neutro-
phils from SR asthma patients were less responsive to
Fig. 2 The effects of dexamethasone on GLCCI1 gene expression by neutrophils from asthmatic patients. Neutrophils were isolated from
peripheral blood of asthmatic patients and then incubated for 18 h in the absence (Con) and presence of asthmatic serum and/or dexamethasone
(DEX) at 10−6 M or 10−4 M. Following culture, GLCCI1 mRNA expression was quantified by realtime-PCR. a and b, Neutrophils respectively from SS
asthmatics (a) and SR asthmatics (b) were incubated with dexamethasone (DEX) at 10−6 M or 10−4 M. c, Neutrophils were isolated from asthmatic
patients and incubated with DEX 10−4 M, and/or asthmatic serum (SE). * P < 0.05 compared with the control groups
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Fig. 3 Cytokine release was inhibited by dexamethasone in patients with SS asthma and SR asthma. Neutrophils from peripheral blood of
asthmatic patients(a, SS asthmatics; b, SR asthmatics) were incubated with dexamethasone (DEX) at 10−6 M or 10−4 M and/or asthmatic serum
(SE) for 18 h. The supernatant was collected and analyzed by ELISA. Data are expressed as the means ± SD (a, b). c, Percentages of IL-8 levels for
DEX or asthmatic serum compared with the amount of IL-8 produced by untreated cells (100%) are shown. * P < 0.05, ** P < 0.01, and *** P < 0.001
compared with the control groups
Fig. 4 Comparison apoptosis of neutrophils from SS asthma and SR asthma patients. Neutrophils were isolated from the peripheral blood of
asthmatic patients and then incubated for 18 h in the absence (Con) or presence of asthmatic serum and/or dexamethasone (DEX) at 10−6 M or
10−4 M. Apoptosis was analyzed by measuring the binding of annexin V-FITC and PI. Data are presented in relation to the control, which was set
at 100%. Data was expressed as the means ± SD. * P < 0.05 compared with the SS asthmatic control groups, # P < 0.05 compared with the SR
asthmatic control groups, + P < 0.05 compared with the SS asthmatic treated with asthmatic serum groups (SE), ξ P < 0.05 compared with the SR
asthmatic treated with asthmatic serum groups (SE)
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DEX, but the constitutive apoptosis was comparable to
that for neutrophils from SS asthmatics.
SR asthmatics are characterized by persistent airway
inflammation despite treatment with corticosteroids, and
therefore these patients could be predisposed to in-
creased airway remodeling and irreversible lung disease
[11, 26, 27]. Given the increasing prevalence and severity
of asthma worldwide, steroid resistance has become a
challenging health problem that imposes enormous bur-
dens on health care [28, 29]. Therefore knowledge of the
mechanisms by which corticosteroids have differential
effects in SS and SR asthma patients is indispensable.
MKP-1 is a phosphatase that dephosphorylates and
inactivates MAPKs, including p38 mitogen-activated
protein kinase (MAPK) [23], and inhibits production of
pro-inflammatory cytokines, which is critical for the anti-
inflammatory functions of corticosteroids [30]. Recent
studies demonstrated increased activation of p38 MAPK
in peripheral blood monocytes from SR asthmatics com-
pared to those from SS asthmatics [31]. MKP-1 has also
been identified by as a marker of in vitro responsiveness
to corticosteroid treatment [20]. These observations
prompted us to determine changes in MKP-1 expression
levels in DEX-treated neutrophils isolated from asthmatic
patients. DEX significantly induced MKP-1 expression in
neutrophils from asthmatics, and this induction is similar
to that seen for other cell types, including mast cells [32],
macrophages [33], osteoblasts [34], monocytes [22] and
airway smooth muscle cells (ASMC) [35]. The induction
of MKP-1 expression by DEX at 10−6 M in neutrophils
from SS asthma patients was higher than that for SR
asthma patients. The sensitivity to glucocorticoids is cor-
related with MKP-1 inducibility, which provides support
for the use of MKP-1 as a potential determinant of cor-
ticosteroid responsiveness. This possibility is consistent
with a previous observation that of increased activation of
p38 MAPK in airway macrophages isolated from severe
asthmatics compared to those from non-severe asth-
matics, and that the severe asthmatic group had impaired
corticosteroid induction of MKP-1 [36]. Atopic asthmatic
serum has been used to mimic the asthmatic milieu to
sensitize airway smooth muscle cells (ASMC) [37, 38]. In
this study, we used atopic asthmatic serum to passively
sensitize neutrophils to simulate asthma conditions in
vitro. Atopic asthmatic serum alone had no effect on
MKP-1 expression by neutrophils, while neutrophil with
both atopic asthmatic serum and DEX impaired DEX-
induced MKP-1 expression in SR asthma patients. These
data suggest that the ability of asthma milieu to reduce
DEX-induced MKP-1 transcription in neutrophils from
SR asthma patients may be associated with corticosteroid
insensitivity.
Insensitivity to glucocorticoid is an important issue in
asthma management, and may lead to poor asthma
control and deterioration of airflow. Whether molecular
glucocorticoid responses have a genetic component has
been extensively examined [39–41]. GLCCI1 was identi-
fied as a novel pharmacogenetic determinant of the re-
sponse of asthma patients to inhaled corticosteroid [24].
Indeed, Tantisira et al. reported that a functional poly-
morphism of GLCCI1 is associated with a substantially
decreased response to inhaled glucocorticoids in patients
with asthma [24]. GLCCI1 expression is rapidly in-
duced by glucocorticoids in murine thymocytes [42].
However, here the GLCCI1 inducibility by DEX in neu-
trophils from asthma patients was invalid . There was
no statistically significant significance in the level of
GLCCI1 in SS and SR asthma neutrophils treated with
DEX or asthmatic serum/DEX. This finding is consist-
ent with previous data, wherein DEX inhibited apop-
tosis of neutrophils from patients with SS asthma and
SR asthma to the same extent. GLCCI1 is thought to be
an early marker of glucocorticoid-induced apoptosis
[42]. The neutrophil apoptosis suppressed by DEX may
contribute to the apparent lack of GLCCI1 expression
induction.
Neutrophils are generally considered to be less sensitive
to GC. However, previous findings confirmed that GCs in-
hibit pro-inflammatory gene expression in neutrophils
from different species [43–45]. IL-8 is a powerful chemo-
attractant and activator of neutrophils that is released by a
variety of cells, including neutrophils [16], and can there-
fore contribute to additional recruitment and activation of
neutrophils in a positive feedback manner if its expression
is not tightly regulated. The gene or protein expression of
IL-8 is increased in asthma patients who are insensitive to
glucocorticoid treatment, as is the case for severe asth-
matic patients [46, 47] and patients with neutrophilic
asthma [48, 49]. We thus investigated whether differential
suppression of MKP-1 expression in SS and SR asthma
patients by DEX influenced IL-8 release from neutrophils.
The results showed a similar inhibition of IL-8 by DEX in
SS asthma and SR asthma patients, but a significantly
higher inhibition was observed in neutrophils from SS
than SR asthma patients treated with the DEX/asthmatic
serum combination, which is consistent with the MKP-1
induction data. The insensitivity to GC of SR asthma neu-
trophils in the presence of a mimetic asthma milieu
should also contribute to lowered responsiveness to the
inhibition of pro-inflammatory cytokine release promoted
by DEX.
Inducing inflammatory cell apoptosis is a key mechan-
ism through which glucocorticoids resolve lymphocytic
and eosinophilic inflammation in asthma [50]. Corticoste-
roids reduce the rate of neutrophil apoptosis to prolong
their survival [25, 51]. In our study, DEX inhibited consti-
tutive neutrophil apoptosis in SS asthma and SR asthma
patients to the same extent. Atopic asthmatic serum
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slightly reduced neutrophil apoptosis in the two groups,
but there was no significant difference between SS asthma
and SR asthma in the presence of atopic asthmatic serum
alone or in combination with DEX. Thus, the apoptosis
that is inhibited by DEX is not associated with insensitivity
to glucocorticoid. The increased number of neutrophils in
the airways of patients with severe asthma [52], may con-
tribute to corticosteroid resistance or refractory disease,
and could be due to the lessened inhibition of pro-
inflammatory cytokine release rather than apoptosis
inhibited by DEX.
Conclusions
DEX exerted different effects on neutrophils from SS
asthma and SR asthma patients. No significant differ-
ences were seen in the apoptosis of neutrophils between
patients with SS asthma and SR asthma, and therefore it
is unlikely that glucocorticoid sensitivity is associated
with the inhibition of apoptosis by glucocorticoid. DEX
induced MKP-1expression and inhibited IL-8 production
by neutrophils, but a reduced MKP-1 mRNA induction
and IL-8 inhibition in response to DEX/asthmatic serum
combination was observed in patients with SR asthma.
This dysfunction may contribute to the insensitivity to
glucocorticoid of these patients.
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